Latest News

Triple therapy revs up immune system against common brain tumor

A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report. Mice with implanted, mouse-derived glioblastoma cells lived an average of 67 days after the triple therapy, compared with mice that lasted 24 days when they received only the two immunotherapies.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • New therapeutic target may improve treatment for brain cancer

  • New compounds could offer therapy for multitude of diseases

  • Stem cells make similar decisions to humans

  • Why good solutions make us oblivious to better ones

  • When attention is a deficit: Sometimes a new strategy makes sense

  • Stereotypes lower math performance in women, but effects go unrecognized

  • For drivers with telescopic lenses, driving experience and training affect road test results

  • Will you ever pay off your student loan?

  • Public Health Responsibility Deal in UK unlikely to be an effective response to alcohol harms

  • Immunotherapy used to reduce memory problems with Alzheimer's disease

  •